Keryx Biopharma - KERX

[DickSIM]

..Ron Bentsur, Chief Executive Officer of Keryx, stated, "We are pleased that this matter has been resolved in a manner that we believe serves the best interests of the Keryx shareholders. This settlement provides us with additional non-dilutive cash to move our compounds into Phase 3 trials."..


portati in cascina $ per il perifosine..
..all'appello mancano quelli di JT per Zerenex..

una notizia al giorno ?

noi possiamo solo attendere!...
qualcuno invece ha fretta!

 

[viralic]

Finalmente è tornata al punto di partenza, ossia l'ultimo prezzo di ieri...così ho potuto incrementare un pò ancora !!!............a 15 euro ne vendo la metà !!!

 

[acqua+]

Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT


http://investors.keryx.com/phoenix.zhtml?c=122201&p=irol-newsArticle&ID=1316742&highlight=

 

[doctor NO]

Finalmente è tornata al punto di partenza, ossia l'ultimo prezzo di ieri...così ho potuto incrementare un pò ancora !!!............a 15 euro ne vendo la metà !!!

no a 150€ se non vai in diarrea prima

 

[acqua+]

no a 150€ se non vai in diarrea prima

io aspetto sereno i 5 $

 

[DickSIM]

io aspetto sereno i 5 $

 

[acqua+]

http://www.selleckchem.com/ProductDetail.asp?ProdId=S1037

 

[DickSIM]

http://www.selleckchem.com/ProductDetail.asp?ProdId=S1037

la peppatenciaaaaaaaaaaaaaaaa!!!!!!!!

costa caro.............

 

[acqua+]

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial ResultsKeryx to Host Investor Conference Call on Thursday, August 6, 2009 at 8:30am EDT

http://investors.keryx.com/phoenix.zhtml?c=122201&p=irol-newsArticle&ID=1317387&highlight=




eqqui ,,,, l'affare si fa sempre + interessante ,,,


Commenting on the quarter, Ron Bentsur, the Company's Chief Executive Officer, remarked, "Keryx has made significant progress over the last few months. We presented important Phase 2 data on both our compounds, regained full compliance with the listing requirements of the Nasdaq Capital Market, and announced our SPA for the Phase 3 trial of perifosine in multiple myeloma. We look forward to finalizing our discussions with the FDA regarding the U.S. Phase 3 program for Zerenex shortly, at which time Keryx will be in the compelling position of having two Phase 3 compounds." Mr. Bentsur added, "I am excited by the opportunity to transform Keryx into a late-stage development company and maximize shareholder value. On behalf of the entire Keryx team, I want to thank all of our shareholders for their continued support."

 

[acqua+]

http://investors.keryx.com/phoenix.zhtml?c=122201&p=irol-SECText&TEXT=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvZmlsaW5nLnhtbD9yZXBvPXRlbmsmaXBhZ2U9NjQ1MDczNSZhdHRhY2g9T04mc1hCUkw9MQ%3d%3d